Lower GI 2016

HIV & ANAL CANCER

Wexler et al ( 2007 )

•

• 32 HIV+ patients treated with CRT ( 5FU+MMC ) between 1997 and 2005

• Median tumour size 2.8 % ; 44% cT1 cN0

5 yr actuarial risk of local failure = 16 %

•

3 / 32 developed distant metastases

•

5 yr overall survival = 65 %

•

5 yr cancer specific survival = 75 %

•

Fraunholz et al ( 2011 )

•

25 HIV + patients and 45 HIV – patients

•

• No difference in T or N stage at diagnosis ( all M0 )

More young males in the HIV+ group

•

No difference in RT dose delivered

•

• 72 % HIV+ received full dose of chemotherapy cf. 91 % HIV- group

CR at 8 wks

5 yr local control

5 yr metastasis free survival

5 yr overall survival

84 %

65 % 86 %

71 %

HIV +

93 % pNS

78 %

91 % pNS

77 % pNS

HIV -

pNS